Q-omics provides the consensus-scored RPS3AP51 profile across patient tissues and cancer cell-line models. RPS3AP51 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPS3AP51 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPS3AP51 RNA expression shows 7,358 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LUSC, COAD, and DLBC as cancer lineages where RPS3AP51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP51 survival associations across molecular data types. RPS3AP51 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP51 RNA expression–survival associations across cancer types. High RPS3AP51 expression shows unfavorable associations in CHOL, ACC and OV, but favorable associations in LUSC, UCS and CESC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify LUSC as the clearest survival context for RPS3AP51 RNA expression.
This table summarizes RPS3AP51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP51 shows lower tumor expression in KICH, LUSC and CHOL and higher tumor expression in COAD and PRAD. The COAD box plot shows higher RPS3AP51 RNA expression in tumor versus normal tissue (log2 FC = +0.153, t-test p = .014).
This table shows molecular features associated with RPS3AP51 in patient tissues and cancer cell lines. In patient samples, RPS3AP51 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
